InMode Ltd.

InMode Ltd. is a global provider of innovative medical technologies, specializing in minimally invasive and non-invasive aesthetic and medical treatments. The company's core business revolves around developing, manufacturing, and marketing platforms that utilize proprietary radio-frequency (RF), light, and laser-based technologies. Headquartered in Yokneam, Israel, InMode's mission is to deliver advanced solutions that enhance beauty and well-being, providing practitioners with effective tools to achieve consistent and repeatable results for their patients.

InMode offers a diverse portfolio of products and services across key market segments including face and body contouring, medical aesthetics, and women's health. Its technologies are applied in various surgical specialties such as plastic surgery, dermatology, gynecology, ENT, and ophthalmology. Notable product platforms include BodyTite, FaceTite, Morpheus8, Evoke, EmpowerRF, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, and IgniteRF, which facilitate procedures like RF-assisted lipolysis, deep subdermal fractional radiofrequency treatments, skin rejuvenation, and permanent hair reduction.

Co-founded by CEO Moshe Mizrahy and CTO Dr. Michael Kreindel in 2008, InMode is publicly traded on NASDAQ under the ticker INMD. The company recently authorized a new share repurchase program in March 2026 for up to approximately 6.38 million shares, representing about 10% of its total outstanding shares. InMode reported fourth-quarter 2025 revenue of $103.9 million and full-year 2025 revenue of $370.5 million. In February 2026, the company concluded a review process for potential takeover proposals, ultimately rejecting all bids. InMode maintains its position as a leading global provider of innovative, energy-based, minimally and non-invasive aesthetic solutions.